4//SEC Filing
Arbet-Engels Christophe 4
Accession 0001104659-25-096678
CIK 0001326190other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 4:23 PM ET
Size
8.5 KB
Accession
0001104659-25-096678
Insider Transaction Report
Form 4
Arbet-Engels Christophe
Chief Medical Officer
Transactions
- Award
Stock Options (option to buy)
2025-10-01+450,000→ 450,000 totalExercise: $3.87Exp: 2035-10-01→ Common Stock, par value $0.0001 (450,000 underlying) - Award
Restricted Stock Units
2025-10-01+150,000→ 150,000 total→ Common Stock, par value $0.0001 (150,000 underlying)
Footnotes (3)
- [F1]The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested
- [F3]The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Documents
Issuer
Altimmune, Inc.
CIK 0001326190
Entity typeother
Related Parties
1- filerCIK 0001802615
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 4:23 PM ET
- Size
- 8.5 KB